Neurocentria, Inc.
Clinical trials sponsored by Neurocentria, Inc., explained in plain language.
-
ADHD combo drug trial halted after just 2 teens enrolled
Symptom relief TerminatedThis study tested whether adding NRCT-101SR to the existing ADHD drug NRCT-202XR could better control symptoms in teenagers aged 13-17. Only 2 participants were enrolled before the trial was stopped early. The goal was to reduce side effects and improve daily functioning, but no …
Phase: PHASE2 • Sponsor: Neurocentria, Inc. • Aim: Symptom relief
Last updated May 26, 2026 12:09 UTC
-
ADHD drug trial for teens halted midway
Symptom relief TerminatedThis study tested a new medicine called NRCT-101SR for teenagers aged 13 to 17 with ADHD. The goal was to see if it could reduce ADHD symptoms better than a placebo. The trial was stopped early, so results are limited.
Phase: PHASE2, PHASE3 • Sponsor: Neurocentria, Inc. • Aim: Symptom relief
Last updated May 26, 2026 12:04 UTC